To the Editor: Translocation t(9;22)(q34;q11) is found in 1-2% of newly diagnosed patients with de novo AML. The prognosis of Ph þ AML is very poor with a median survival time of only 7 months. We present two patients with de novo Ph þ AML who received induction chemotherapy and post-remission imati
Comparative molecular analysis of therapy-related and de novo acute promyelocytic leukemia
✍ Scribed by T. Ottone; L. Cicconi; S.K. Hasan; S. Lavorgna; M. Divona; M.T. Voso; E. Montefusco; L. Melillo; E. Barragán; U. Platzbecker; L. Giannì; M. Hubmann; M. Pagoni; S. Amadori; F. Lo-Coco
- Book ID
- 113773591
- Publisher
- Elsevier Science
- Year
- 2012
- Tongue
- English
- Weight
- 153 KB
- Volume
- 36
- Category
- Article
- ISSN
- 0145-2126
No coin nor oath required. For personal study only.
📜 SIMILAR VOLUMES
As a single agent, all-trans RA produces a higher rate of complete remission in APL than any other drug in any other neoplastic disease. The molecular findings in this illness have been exploited to develop a means of detecting and eradicating minimal residual disease. Compared with other forms of a
The primary cytogenetic abnormality in acute promyelocytic leukemia (APL; FAB M3) is a reciprocal translocation, t( 15; I7)(q22;q I2), which serves t o fuse the PML gene on chromosome I5 t o the retinoic acid receptor alpha (RAM) gene on chromosome 17. A PML-MM fusion message transcribed from the de